MPN

Cancer Medicine

The Lancet Haematology

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

Cancers

Predictors of response to hydroxyurea and switch to ruxolitinib in HU-resistant polycythaemia vera patients: A real-world PV-NET study

Biomedicines

Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) project

Journal of Hematology & Oncology

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

Journal of Clinical Oncology

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial

Thrombosis Research

Atrial fibrillation and peripheral arterial disease define MPN patients with very high risk of thrombosis

HemaSphere

Outcome of 129 pregnancies in polycythemia vera patients: A report of the European LeukemiaNET

Blood Advances

Prevalence and association of frailty with clinical outcomes in myeloproliferative neoplasms: A population-based study

eJHaem

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study

Current Hematologic Malignancy Reports

Pelabresib (CPI-0610): An exciting novel drug for the treatment of myelofibrosis

Current Treatment Options in Oncology

Essential thrombocythemia in adolescents and young adults: Clinical aspects, treatment options and unmet medical needs

Annals of Hematology

Real-world treatments and thrombotic events in polycythemia vera patients in the USA

American Journal of Translational Research

Comparability of JAK2 p.V617F allele burden in peripheral blood and that in bone marrow in patients with suspected myeloproliferative neoplasms: a single-center prospective study

Journal of the European Academy of Dermatology and Venerology

Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients

Blood

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Blood Advances

Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea

Journal of Clinical Oncology

MANIFEST: Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve myelofibrosis

Transplantation and Cellular Therapy

Comparison of pretransplantation prediction models for nonrelapse mortality in patients with myelofibrosis undergoing allogeneic stem cell transplantation

Frontiers in Oncology

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine

Targeted Oncology

Study of parsaclisib plus ruxolitinib in myelofibrosis discontinued

Clinical Advances in Hematology & Oncology

A review of essential thrombocythemia and its complications

Annals of Oncology

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Cancer Medicine

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project

American Journal of Hematology

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management

Cancer Medicine

Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high-risk essential thrombocythemia

British Journal of Hematology

Characterization of myeloproliferative neoplasms in the paediatric and young adult population

Journal of the American Heart Association

In‐hospital outcomes of acute myocardial infarction with essential thrombocythemia and polycythemia vera: Insights from the National Inpatient Sample

The Lancet

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

2022 American Society of Hematology Annual Meeting Abstract

Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-1 risk myelofibrosis

2022 American Society of Hematology Annual Meeting Abstract

Bone marrow fibrosis changes do not correlate with efficacy outcomes in myelofibrosis: Analysis of more than 300 JAK inhibitor-naïve patients treated with momelotinib or ruxolitinib

2022 American Society of Hematology Annual Meeting Abstract

Ruxolitinib versus best available therapy for PV intolerant or resistant to hydroxycarbamide in a randomized trial

2022 American Society of Hematology Annual Meeting Abstract

Ropeginterferon alfa-2b versus standard therapy for low-risk patients with polycythemia vera. Final results of Low-PV randomized phase II trial

2022 American Society of Hematology Annual Meeting Abstract

Ruxolitinib versus best available therapy in patients with essential thrombocythemia: Pre-specified interim analysis of the randomized phase 2b ruxobeat clinical trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

American Journal of Hematology

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms

Blood

Essential thrombocythemia: challenges in clinical practice and future prospects

American Journal of Hematology

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival

Journal of Cardiology

Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation

Therapeutic Advances in Chronic Disease

Characteristics of myeloproliferative neoplasm-associated portal hypertension and endoscopic management of variceal bleeding

BioMed Research International

The predictive value of neutrophil-lymphocyte ratio in patients with polycythemia vera at the time of initial diagnosis for thrombotic events

Frontiers in Oncology

Allogeneic hematopoietic stem cell transplantation for mixed or overlap myelodysplastic/myeloproliferative disorders

Research and Practice in Thrombosis and Haemostasis

Patients with myeloproliferative neoplasms and COVID-19 have increased rates of arterial thrombosis

The ASCO Post

FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 Rearrangement

Future Oncology

SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia

Diagnostics

Impact of anti-endothelial cell antibodies (AECAs) in patients with polycythemia vera and thrombosis

Blood Advances

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

Cancer

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes

Future Oncology

Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review

Leukemia & Lymphoma

Recent advances in the treatment of polycythemia vera

International Journal of Hematology

Treatment options and pregnancy management for patients with PV and ET

Cancer

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis

The Lancet Hematology

Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

Thrombosis Research

Thrombosis in patients with post-polycythemia vera myelofibrosis: incidence and risk factors

Leukemia Research

Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia

Journal of Clinical Oncology

Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients

ASCO Abstract

MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor

Journal of Clinical Oncology

An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms

Journal of Clinical Oncology

Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study

International Journal of Hematology

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives

JMIR Formative Research

Mobile app intervention on reducing the myeloproliferative neoplasm symptom burden: pilot feasibility and acceptability study

Therapeutic Advances in Hematology

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

Annals of Hematology

Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Scientific Reports

Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis

Korean Journal of Internal Medicine

How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey

Journal of Oncology Pharmacy Practice

Management of myeloproliferative neoplasms (MPNs)

International Journal of Molecular Sciences

Second cancer onset in myeloproliferative neoplasms: what, when, why?

Managed Healthcare Executive

NCCN adds newly approved long-acting interferon to its practice guidelines for polycythemia vera

Blood

A randomized, phase 3, trial of interferon-α versus hydroxyurea in polycythemia vera and essential thrombocythemia

OncLive

Future of myelofibrosis treatment is moving beyond just JAK inhibition

Cells

How we manage myelofibrosis candidates for allogeneic stem cell transplantation

Leukemia Research

Characterizing frailty in myeloproliferative neoplasms: results from the ORCHID study

Blood Advances

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Journal of Clinical Oncology

Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy

OncLive

FDA approves pacritinib for intermediate- or high-risk myelofibrosis with severe thrombocytopenia

The Lancet Haematology

Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials

Leukemia

Second versus first wave of COVID-19 in patients with MPN

Cancer

Improved survival of patients with myelofibrosis in the last decade: Single-center experience

Healio

Momelotinib improves outcomes in pretreated myelofibrosis

2021 American Society of Hematology Annual Meeting Abstract

Final results of a phase 2 study of sotatercept (ACE-011) for anemia of MPN-associated myelofibrosis

2021 American Society of Hematology Annual Meeting Abstract

A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLNFGFR1)

2021 American Society of Hematology Annual Meeting Abstract

Disease-modifying potential of BET inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis – preliminary data

2021 American Society of Hematology Annual Meeting Abstract

Safety and tolerability of fedratinib (FEDR), an oral inhibitor of janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): results from the phase 3b FREEDOM trial

2021 American Society of Hematology Annual Meeting Abstract

Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy

Annals of Hematology

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

CancerNetwork

FDA Approves Ropeginterferon Alpha-2b for Polycythemia Vera

European Journal of Haematology

Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients

Cancers

Recent advances in molecular diagnostics and targeted therapy of myeloproliferative neoplasms

Current Hematologic Malignancy Reports

Philadelphia-negative myeloproliferative neoplasms around the COVID-19 pandemic

Leukemia & Lymphoma

Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States

American Journal of Hematology

Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

Journal of Cardiovascular Pharmacology

NOAC in patients with VTE and polycythemia vera or essential thrombocythemia

International Society on Thrombosis and Haemostasis 2021 Congress (Abstract)

Thrombotic complications in a cohort of children with myeloproliferative neoplasms

BMC Cancer

Tobacco use in the myeloproliferative neoplasms: symptom burden, patient opinions, and care

Frontiers in Immunology

Allogeneic hemopoietic stem cell transplantation for myelofibrosis: 2021

Journal of Hematology & Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Journal of Clinical Nursing

Daily living and rehabilitation needs in patients and caregivers affected by myeloproliferative neoplasms (MPN): A qualitative study

2021 American Society of Clinical Oncology Annual Meeting (Abstract)

Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis

2021 European Hematology Association 2021 Virtual Congress (Abstract)

Improved transfusion independence rates for momelotinib vs ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status

2021 European Hematology Association 2021 Virtual Congress (Abstract)

Rusfertide (PTG-300) eliminates the need for therapeutic phlebotomy in both low and high-risk polycythemia vera (PV) patients

2021 European Hematology Association Virtual Congress (Abstract)

Navitoclax and ruxolitinib for patients with myelofibrosis and JAK inhibitor experience: response duration in phase 2 study

2021 European Hematology Association Virtual Congress (Abstract)

An epidemiological study of the cardiovascular health and thrombotic risk profiles of patients with myeloproliferative neoplasms in primary care across the United Kingdom

Cancer Imaging

The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review

American Journal of Hematology

Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations

Blood Advances

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Bone Marrow Transplantation

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

Cancer Network

Parsaclisib plus ruxolitinib to treat myelofibrosis improves spleen size and symptom burden

Blood Cancer Journal

Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program

Acta Haematologica

Clinical benefit derived from decitabine therapy for advanced phases of myeloproliferative neoplasms

Frontiers in Oncology

Evaluation of therapeutic strategies to reduce the number of thrombotic events in patients with polycythemia vera and essential thrombocythemia

Blood Cancer Journal

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Blood Advances

A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms

Hematology/Oncology and Stem Cell Therapy

2021 Transplant and Cellular Therapy Meetings (Abstract)

Peri-Transplant Administration of Ruxolitinib (Rux) in Patients with Myelofibrosis (MF) Is Safe and Effective. a Pilot Study

Blood Advances

Survival following allogeneic transplant in patients with myelofibrosis

2020 ASH Annual Meeting (Abstract)

Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients

2020 ASH Annual Meeting (Abstract)

Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension

Targeted Oncology

Long-term safety of fedratinib in patients with intermediate- or high-risk myelofibrosis (MF)

2020 ASH Annual Meeting (Abstract)

Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

2020 ASH Annual Meeting (Abstract)

Clinical Characteristics and Treatment Patterns By Risk Stratification in Patients with Essential Thrombocythemia: An Analysis of the MOST Study

Hematology ASH Education Program 2020

Genomics of MPN progression

Expert Review of Hematology

Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms

Cancers

Novel concepts of treatment for patients with myelofibrosis and related neoplasms

Cancer Medicine

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition

Leukemia

Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis

Cancers

Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study

Leukemia & Lymphoma

Highly increased risk of fracture in patients with myeloproliferative neoplasm

OncLive

MPL Mutations Linked to Increased Risk of Myelofibrosis Transformation in Essential Thrombocythemia

British Journal of Haematology

Cytoreductive treatment in patients with CALR‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

OncLive

Pacritinib Pretreatment Demonstrates Intriguing Interim Findings in Myelofibrosis

Journal of the Advanced Practitioner in Oncology

Management of Thrombosis in Polycythemia Vera: The Advanced Practitioner Perspective

British Journal of Haemtology

Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

Thrombosis Research

Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

Leukemia

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

British Journal of Haematology

‘MPN Genomic Calculator’: real‐life use in a young population with essential thrombocythaemia

2020 European Hematology Associated Annual Congress

Treatment and disease management practices in patients with MPNs in 6 countries: an expansion of the MPN LANDMARK survey

Leukemia

Risk of infections in patients with myeloproliferative neoplasms—a population-based cohort study of 8363 patients

Blood

Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study

Integrative Cancer Therapies

Associations between global mental health and response to an app-based meditation intervention in myeloproliferative neoplasm patients

Blood Advances

Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden

Therapeutic Advances in Hematology

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis

Cancer Therapy Advisor

Characteristics of ruxolitinib discontinuation syndrome in myelofibrosis

Targeted Oncology

RAS/MAPK pathway mutations show association with adverse survival outcomes in myelofibrosis

Targeted Oncology

Ph-negative MPNs with pulmonary hypertension associated with poor outcomes

Leukemia & Lymphoma

Healthcare resource utilization in myeloproliferative neoplasms: A population-based study from Ontario, Canada

Blood

US OPTUM database study in polycythemia vera patients: Thromboembolic events (TEs) with hydroxyurea (HU) vs ruxolitinib switch therapy and machine-learning model to predict incidence of TEs and HU failure

Oncology Nursing News

FDA accepts BLA for ropeginterferon alfa-2b for PV treatment

Hematological Oncology

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data

Journal of Medical Economics

Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis

EClinicalMedicine

Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study

Current Hematologic Malignancy Reports

Myeloproliferative neoplasms in children, adolescents, and young adults

Clinical Lymphoma, Myeloma & Leukemia

Treatment patterns and blood counts in patients with polycythemia vera treated with hydroxyurea in the United States: An analysis from the REVEAL study

Blood

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Cancer Chemotherapy and Pharmacology

Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects

American Journal of Hematology

Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies

Blood

Persistent leukocytosis in polycythemia vera Is associated with disease evolution but not thrombosis

American Journal of Hematology

Second cancers in MPN: Survival analysis from an international study

Lancet Haematology

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study

Haeamtologica

Ruxolitinib And interferon-Α2 combination therapy for patients with polycythemia vera or myelofibrosis: A Phase II study

Leukemia Research

A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)

British Journal of Haematology

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Lancet Haematology

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study